Mylan announced the U.S FDA's final approval of its Abbreviated New Drug Application (ANDA) for repaglinide tablets (0.5, 1, and 2 mg), the generic version of Novo Nordisk's (Denmark) Prandin, indicated for glycemic control in adults with type 2 diabetes adjunct to diet and exercise. Furthermore, Mylan has now launched the generic product in the United States.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.82 USD | +3.91% |
|
+8.26% | +8.86% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.86% | 1.35TCr | |
+57.04% | 85TCr | |
+31.64% | 63TCr | |
+0.09% | 36TCr | |
+15.45% | 32TCr | |
+12.70% | 30TCr | |
+15.51% | 24TCr | |
+16.72% | 23TCr | |
+16.34% | 18TCr | |
+4.08% | 17TCr |
- Stock Market
- Equities
- VTRS Stock
- News Viatris Inc.
- Mylan Launches Generic Version of Novo Nordisk's Diabetes Drug Prandin